Want to see NZ:EBO full AI Analyst Report?
Top Page
EBOS Group Limited
(EBO)
Select Model
Select Model
Rating:60Neutral
Price Target:
$19.50
▼(-7.89% Downside)
Action:N/A
Date:10/05/26
The score is held back primarily by weaker financial consistency (FY2026 revenue and margin deterioration) and bearish technical momentum (downtrend across key moving averages, negative MACD). Offsetting factors include a supportive valuation profile (moderate P/E and high dividend yield) and a solid earnings-call outlook with FY27 EBITDA growth guidance and improving free-cash-flow expectations from lower CapEx, despite acknowledged headwinds.
Positive Factors
Diversified healthcare and animal care growth
Growth across healthcare, animal care, retail pharmacy and logistics reduces reliance on a single end market. The breadth of these channels supports recurring distribution volumes, creates cross-selling opportunities and gives EBOS multiple avenues to sustain earnings over the next several quarters.
Negative Factors
Recent margin compression and unstable earnings profile
Material margin contraction reduces confidence that revenue growth will translate consistently into profit. Even with FY26 net income broadly flat, lower gross and operating margins leave less buffer against cost inflation, competitive pressure or mix changes and could constrain earnings quality over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified healthcare and animal care growth
Growth across healthcare, animal care, retail pharmacy and logistics reduces reliance on a single end market. The breadth of these channels supports recurring distribution volumes, creates cross-selling opportunities and gives EBOS multiple avenues to sustain earnings over the next several quarters.
Read all positive factors
EBOS Group Limited (EBO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.92B
Dividend Yield6.57%
Average Volume (3M)228.14K
Price to Earnings (P/E)14.4
Beta (1Y)0.94
Revenue Growth16.36%
EPS Growth5.52%
CountryNZ
Employees5,364
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.07
Shares Outstanding209,054,120
10 Day Avg. Volume195,223
30 Day Avg. Volume228,138
Financial Highlights & Ratios
PEG Ratio-4.37
Price to Book (P/B)1.55
Price to Sales (P/S)0.33
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$29.54Price Target Upside39.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.18
Revenue Forecast (FY)$13.92B
EBOS Group Limited Business Overview & Revenue Model
Company Description
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The c...
How the Company Makes Money
EBOS primarily makes money by acting as a large-scale distributor and supply-chain partner for healthcare and related products. Its core revenue model is business-to-business sales: it purchases pharmaceuticals, medical consumables/devices, and ot...
EBOS Group Limited Earnings Call Summary
Earnings Call Date:Aug 18, 2026
(Q4-2026)
| Next Earnings Date:Feb 23, 2027
Earnings Call Sentiment Positive
The call communicated solid top‑line growth, completion of a major A$360m infrastructure program that materially reduces future capital needs, meaningful momentum in higher-growth divisions (Animal Care, Medical Technology, Retail Pharmacy Brands) and a disciplined M&A and capital allocation approach. Temporary headwinds were acknowledged — notably FX translation, fuel costs, margin pressure and a known NZ contract roll-off — but management framed these as manageable or transitory and backed guidance that excludes further acquisitions. Balance sheet metrics, free cash flow generation and a maintained dividend were highlighted as strengths. Overall the positives (portfolio re‑positioning, completed investment cycle, strong divisional growth and capital flexibility) outweigh the measurable but contained lowlights.Positive Updates
Revenue and Underlying EBITDA Growth
Group revenue rose 9.9% to A$13.5bn and underlying EBITDA increased 5% to A$614m; underlying NPAT was A$250m. On a statutory basis EBITDA was up 7.8% and NPAT up 4.7%.
Negative Updates
Fuel and Foreign Exchange Headwinds
Management cited approximately A$22m of combined fuel and FX headwinds in FY'26 (fuel impact around A$5m). A stronger Australian dollar — a 13‑year high vs the NZD — materially affected translated earnings and purchasing costs (notably in Medical Technology).
Read all updates
Q4-2026 Updates
Positive
Negative
Revenue and Underlying EBITDA Growth
Group revenue rose 9.9% to A$13.5bn and underlying EBITDA increased 5% to A$614m; underlying NPAT was A$250m. On a statutory basis EBITDA was up 7.8% and NPAT up 4.7%.
Read all positive updates
Company Guidance
EBOS guided FY27 underlying EBITDA of A$635–655 million (midpoint ~A$645m), implying mid‑single‑digit EBITDA growth and explicitly excluding any new acquisitions; CapEx is expected to normalise to ~A$100m (down from A$145m in FY26), supporting stronger free cash flow after FY26 reported free cash flow of A$204m and facilitating ~A$150m of additional bolt‑on M&A capacity within a leverage ceiling of 2.3x (FY26 leverage 2.1x, target range 1.7–2.3x) and with A$726m undrawn committed facilities and WA debt maturity >3 years. Management also flagged a targeted 30% productivity uplift at Kemps Creek by end FY27, stable cash conversion days (~20) and only A$7m NWC growth on 10% revenue growth, while noting depreciation and financing costs will be elevated as recent investments are annualised and the final dividend was maintained at A$0.615 per share.EBOS Group Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
64
Positive
Cash Flow
62
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.84B | 12.20B | 13.15B | 12.25B | 10.77B |
| Gross Profit | 910.40M | 1.63B | 1.63B | 1.56B | 1.25B |
| EBITDA | 531.22M | 535.45M | 591.65M | 572.98M | 398.25M |
| Net Income | 214.33M | 213.89M | 270.67M | 253.57M | 203.26M |
Balance Sheet | |||||
| Total Assets | 7.83B | 7.24B | 6.72B | 6.44B | 6.28B |
| Cash, Cash Equivalents and Short-Term Investments | 239.29M | 183.19M | 216.18M | 212.05M | 518.99M |
| Total Debt | 1.90B | 1.61B | 1.64B | 1.28B | 1.65B |
| Total Liabilities | 5.12B | 4.53B | 4.31B | 4.14B | 4.13B |
| Stockholders Equity | 2.75B | 2.72B | 2.45B | 2.44B | 2.27B |
Cash Flow | |||||
| Free Cash Flow | 207.07M | 365.99M | 262.89M | 293.26M | 159.62M |
| Operating Cash Flow | 332.10M | 416.08M | 347.11M | 391.68M | 249.54M |
| Investing Cash Flow | -258.79M | -366.72M | -376.90M | -154.39M | -1.40B |
| Financing Cash Flow | -11.74M | -84.41M | 34.22M | -547.56M | 1.51B |
EBOS Group Limited Technical Analysis
Negative
21.17
Price Trends
20.71
Negative
20.48
Negative
21.80
Negative
Market Momentum
-0.47
Positive
25.88
Positive
21.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:EBO, the sentiment is Negative. The current price of 21.17 is above the 20-day moving average (MA) of 19.80, above the 50-day MA of 20.71, and below the 200-day MA of 21.80, indicating a bearish trend. The MACD of -0.47 indicates Positive momentum. The RSI at 25.88 is Positive, neither overbought nor oversold. The STOCH value of 21.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:EBO.
EBOS Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $27.05B | 58.10 | 22.84% | 1.63% | 15.59% | 23.94% | |
60 Neutral | $3.92B | 14.35 | 7.99% | 6.57% | 16.36% | 5.52% | |
56 Neutral | $1.83B | -10.88 | -4.17% | 3.15% | 11.86% | 72.99% | |
54 Neutral | $458.30M | 30.91 | 14.07% | 0.67% | 22.44% | 23.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $13.62M | -3.87 | -75.57% | ― | 42.20% | 23.68% | |
42 Neutral | $310.47M | -6.27 | -190.54% | ― | -47.36% | -3.79% |
* Healthcare Sector Average
NZ:EBO
EBOS Group Limited
18.50
-9.44
-33.78%
NZ:FPH
Fisher & Paykel Healthcare Corporation Limited
46.57
9.52
25.70%
NZ:PEB
Pacific Edge Limited
0.24
0.04
23.08%
NZ:RYM
Ryman Healthcare
1.80
-0.91
-33.52%
NZ:TRU
TruScreen Group Ltd.
0.01
>-0.01
-29.41%
NZ:AFT
AFT Pharmaceuticals Ltd.
4.30
1.51
54.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.